Fractyl Health
Working to liberate patients, empower physicians and lower health care costs by developing device-based solutions to metabolic diseases.
| USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | (23 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (36463 %) | (119099 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (64243 %) | (73865 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | 31698 % | 75775 % |
Source: Company filings or news article
Related Content
Fractyl is a pioneering healthcare startup that is focused on developing innovative therapies for the treatment of Type 2 Diabetes (T2D) and obesity. The company's primary market is patients suffering from these metabolic diseases. The company's mission is to create transformative therapies that can prevent and eliminate these diseases by targeting their root causes.
Fractyl's business model revolves around the development and commercialization of its breakthrough therapies. The company's main product in development is Rejuva, a novel gene therapy platform that is designed to improve the function of islet cells in the pancreas, which play a crucial role in regulating blood sugar levels. By enhancing the function of these cells, Fractyl aims to enable long-term remission of T2D and obesity.
Rejuva is currently in the preclinical development stage and is being tested under the oversight of the United States Food & Drug Administration (FDA). While it has not yet received full regulatory approval, it has shifted from investigational use to commercial availability with a CE mark, which indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area.
Fractyl generates revenue through the development, regulatory approval, and subsequent commercialization of its therapies. The company's financial success hinges on the successful development and approval of its products, as well as their acceptance and adoption by healthcare providers and patients.
Keywords: Healthcare, Type 2 Diabetes, Obesity, Gene Therapy, Metabolic Diseases, Pancreatic Islet Cells, Rejuva, FDA, CE Mark, Commercialization.